• BfB Labs white paper spotlights the intensifying crisis in children and young people’s mental healthcare and outlines the case for accelerating the integration of digital interventions.
• White paper maps a new care pathway integrating digital solutions into young people’s mental healthcare.
• 4 out of 10 (36.36 percent) of Child and Adolescent Mental Health Services (CAMHS) have not adopted any new digital mental health supports for children and young people (CYP) since the onset of COVID-19.
A new white paper ‘Future of Children’s Mental Health: Making the case for accelerating the integration of digital therapeutics’ which was published in October, spotlights the intensifying crisis and outlines why widespread adoption of digital therapeutics is being hindered by a lack of digital literacy making it difficult for commissioners to evaluate new interventions. Published by BfB Labs, a pioneering UK company that is using emergent technology to tackle the status quo in children’s mental healthcare to ensure equitable access to early interventions that improve lifelong outcomes for children.
“The pandemic demands an imperative to make digital mental health therapeutics a routine part of early access and early intervention.” said Manjul Rathee, CEO of BfB Labs “Even when a digital therapeutic has been approved by the Medicines Healthcare Regulatory Authority (MHRA), is CE marked, has demonstrated high levels of safety, efficacy, and has good economic data, this still does not guarantee widespread adoption. Multiple barriers remain, including an organisation’s attitude to risk, and difficulties identifying and evaluating interventions.”
BfB Labs whitepaper provides intelligence on the current status quo and paints a clear picture of the roadblocks and also maps where forward-thinking CAMHS organisations can integrate digital therapeutics into children and young people’s mental healthcare pathways to effectively meet surging demand for help.
“According to Manjul Rathee “Meeting the scale of support required, demands moving beyond rhetoric to upskilling and evolving services to meet young people where they are today – on their mobile or tablet.”
BfB Labs recently announced it had received regulatory approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Lumi Nova – the first mobile game for paediatric anxiety disorders that provides ongoing evidence.